The ingredient targets the ‘y-zone’, according to Givaudan, which is the face and neck area, and acts to energise and reshape skin cells.
Alongside this, the ingredients player has also launched its Adaptogenes Botanicals Solution, a collection made of 10 botanical extracts including moringa, turmeric, aloe vera and acerola to chill the skin and the body.
Mélanie Duprat, Category Manager said, "The health and wellness market has grown from an industry to a culture. Adaptogenes are real treasures that abound in many plant extracts.
“Each one has its features but all can help regulate processes in the body and adapt to give the skin what it needs at a given point in time.
“Thanks to our unique expertise in plant extraction, we have pulled the best of each plant, especially moringa and turmeric, to develop this collection.”
Givaudan is a global leader in the creation of flavours and fragrances. Its active beauty division offers an extensive portfolio of active cosmetic ingredients.
Digital inspiration
Givaudan is marketing its Agefinity ingredient with a focus on how consumer lifestyles are being impacted by digital device usage.
Romain Reynaud, R&D Director, said: “This common lifestyle leads to a new beauty issue identified as ‘Text Neck Wrinkles’, the newest challenge brilliantly highlighted by our team of researchers.
“Their exceptional scientific research and results have influenced the creation of Agefinity which is inspired by nature and activated by biotechnology.”
Agefinity is a mannose-6-Phosphate complex using a vegetal source and green chemistry to replenish the energy of the cells.
With multiple anti-ageing benefits, Givaudan says aAgefinity can significantly reduce visible age spots (a reduction up to 2.1 times more efficient), neck (-32.5%) and crow’s feet (-11.5%) wrinkles, remodel the Y-shape of the face and reorganize skin matrix similar to younger skin.
Further, 74% of the panel found the skin on their neck firmer (vs 45% for placebo) and 84% felt convinced by the effect of the product at the end of the trial (vs 60% for placebo).
